David P. Nicolau - Concepedia

Author

David P. Nicolau

Also Known As

D NICOLAU, D Nicolau, D P Niclau, D P Nicolau, D. Nicolau, D. P Nicolau, D. P. Nicolau, D.P Nicolau, D.P. Nicolau, David Nicolau

931

Publications

24.1K

Citations

H-Index

168

Concepts

All Affiliations

Hartford Hospital Hartford Financial Services (United States)University of Connecticut

About

David P. Nicolau is an author at Hartford Hospital specializing in medicine, antimicrobial resistance, and drug resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	40	100	4.8K
2	Education	2	2	54
3	Arts	1	1	38
4	Business	1	1	39
5	Engineering	1	1	15

David P. Nicolau

454

Publications

18.2K

Citations

H-Index

Page 1

	Year	Citations
Experience with a once-daily aminoglycoside program administered to 2,184 adult patients David P. Nicolau, Collin D. Freeman, Paul Belliveau, Antimicrobial Agents and Chemotherapy PharmacotherapyAntimicrobial ChemotherapyDrug ResistanceDrug MonitoringOda Program	1995	633
Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections Chonghua Li, Xiaoli Du, Joseph L. Kuti, Antimicrobial Agents and Chemotherapy PharmacotherapyPharmacodynamic ModelingDrug ResistanceAntimicrobial StewardshipRespiratory Infection	2007	291
Novel Dual-Targeting Benzimidazole Urea Inhibitors of DNA Gyrase and Topoisomerase IV Possessing Potent Antibacterial Activity: Intelligent Design and Evolution through the Judicious Use of Structure-Guided Design and Stucture−Activity Relationships Paul S. Charifson, Anne‐Laure Grillot, Trudy H. Grossman, Journal of Medicinal Chemistry Bioorganic ChemistryAntibacterial ActivityMolecular BiologyChemical BiologyPharmaceutical Chemistry	2008	222
Pharmacodynamic Comparisons of Levofloxacin, Ciprofloxacin, and Ampicillin against <i>Streptococcus pneumoniae</i> in an In Vitro Model of Infection Melinda K. Lacy, Wen Lu, Xiaowei Xu, Antimicrobial Agents and Chemotherapy	1999	217
Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae Catharine C. Bulik, David P. Nicolau Antimicrobial Agents and Chemotherapy Antibiotic AdjuvantKlebsiella PneumoniaeCarbapenemase-producing Klebsiella PneumoniaeAntimicrobial ChemotherapyVitro Chemostat	2011	197
Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem Joseph L. Kuti, Prachi K. Dandekar, Charles H. Nightingale, The Journal of Clinical Pharmacology	2003	196
Relationship between Fluoroquinolone Use and Changes in Susceptibility to Fluoroquinolones of Selected Pathogens in 10 United States Teaching Hospitals, 1991-2000 Marcus Zervos, Ellie Hershberger, David P. Nicolau, Clinical Infectious Diseases Preventive MedicineHealth SciencesAntimicrobial SusceptibilityFluoroquinolone UseMedicine	2003	169
Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients Chonghua Li, Joseph L. Kuti, Charles H. Nightingale, The Journal of Clinical Pharmacology	2006	166
Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia David P. Nicolau, JoCarol McNabb, Melinda K. Lacy, International Journal of Antimicrobial Agents Klebsiella PneumoniaePatient SafetyAcute CareSepsisNosocomial Pneumonia	2001	157
Adherence to Highly Active Antiretroviral Therapy Predicts Virologic Outcome at an Inner‐City Human Immunodeficiency Virus Clinic JoCarol McNabb, Jack Ross, Kenneth Abriola, Clinical Infectious Diseases Sexual HealthEpidemiologyPreventive MedicineInjection Drug UsersTreatment And Prevention	2001	154

Page 1